Redmile Group’s VanEck Biotech ETF BBH Stock Holding History

Redmile Group’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-3,208	Closed	-$292K	–	49
2014 Q1	$292K	Buy	+3,208	New	+$312K	0.03%	52

Other funds holding BBH

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

LFM

Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

AHS

Aspiriant Holdings S3 Los Angeles, California $233M AUM 3.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

ECML

Eagle Capital Management (Louisiana) Mandeville, Louisiana $293M AUM 33.65% 1-Year Est. Return

Redmile Group's BBH Position: Q2 2014 in Review

Redmile Group sold out of VanEck Biotech ETF (BBH) in Q2 2014, closing a stake of 3,208 shares — an estimated $292K sold.

Redmile Group first reported a position in BBH in Q1 2014 and held it in 1 quarter. The position peaked at $292K in Q1 2014. 59 funds tracked by Wall St. Rank hold BBH as of Q2 2014.

Redmile Group reported no remaining VanEck Biotech ETF position as of Q2 2014 after selling out during the quarter.
Redmile Group sold 3,208 VanEck Biotech ETF shares in Q2 2014, an estimated $292K.
Redmile Group first reported a position in VanEck Biotech ETF in Q1 2014 and held it in 1 quarter.
Redmile Group's VanEck Biotech ETF position peaked at $292K in Q1 2014.
59 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2014.

Based on Redmile Group's 13F filing for Q2 2014, filed 15 Aug 2014.